GT Biopharma (GTBP)
(Delayed Data from NSDQ)
$3.35 USD
-0.41 (-10.84%)
Updated Apr 26, 2024 03:13 PM ET
After-Market: $3.21 -0.14 (-4.04%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Cash flow Statements
Fiscal Year End for GT Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -7.60 | -20.88 | -58.01 | -28.30 | -38.65 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.32 | 0.51 |
Net Change from Assets/Liabilities | 1.94 | -1.89 | 7.97 | 17.07 | 2.94 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -3.19 | 7.56 | 34.44 | 3.65 | 31.54 |
Net Cash From Operating Activities | -8.85 | -15.22 | -15.61 | -7.26 | -3.66 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -2.01 | 12.15 | -23.04 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -2.01 | 12.15 | -23.04 | 0.00 | 0.20 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.27 | 0.00 | 41.11 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 1.21 | 12.53 | 3.43 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -0.22 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 6.27 | -0.22 | 42.32 | 12.53 | 3.43 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -4.59 | -3.30 | 3.67 | 5.27 | -0.03 |
Cash at Beginning of Period | 5.67 | 8.97 | 5.30 | 0.03 | 0.06 |
Cash at End of Period | 1.08 | 5.67 | 8.97 | 5.30 | 0.03 |
Diluted Net EPS | -5.64 | -19.82 | -61.86 | -193.69 | -342.18 |
Fiscal Year End for GT Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -7.60 | -4.64 | -2.22 | -0.23 |
Depreciation/Amortization & Depletion | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | NA | 1.94 | 1.45 | 1.05 | -0.02 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | -3.19 | -3.62 | -3.68 | -2.66 |
Net Cash From Operating Activities | NA | -8.85 | -6.81 | -4.84 | -2.91 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -2.01 | -2.49 | -4.33 | -6.99 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -2.01 | -2.49 | -4.33 | -6.99 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 6.27 | 6.27 | 6.27 | 6.27 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 6.27 | 6.27 | 6.27 | 6.27 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -4.59 | -3.02 | -2.91 | -3.63 |
Cash at Beginning of Period | NA | 5.67 | 5.67 | 5.67 | 5.67 |
Cash at End of Period | NA | 1.08 | 2.65 | 2.77 | 2.05 |
Diluted Net EPS | NA | -2.04 | -1.80 | -1.50 | -0.30 |